menu
    • menu
    [{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Aesthetics \/ Merz Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Merz Aesthetics \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Merz Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merz Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Merz Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Hydroxylapatite","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Aesthetics \/ Merz Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"Merz Aesthetics \/ Merz Aesthetics"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Merz Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Aesthetics \/ Merz Aesthetics","highestDevelopmentStatusID":"8","companyTruncated":"Merz Aesthetics \/ Merz Aesthetics"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merz Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merz Aesthetics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Merz Aesthetics

    Menu

    Merz Aesthetics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

                            Details : Botulinum toxin type A is a Protein drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Skin Aging.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 07, 2025

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of NT 201 Doses in the Treatment of Platysma Prominence

                            Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 17, 2023

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Zel Skin and Laser Specialists

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

                            Details : Incobotulinumtoxin A is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alopecia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 13, 2022

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Zel Skin and Laser Specialists

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Merz Aesthetics to Showcase New Data at the 20th Aesthetics & Anti-Aging Medicine World Congress 2022

                            Details : Study Design of LONG RUN: A LONGitudinal evaluation and real-world evidence of uniquely purified incobotulinumtoxinA in treatment naïve participants, demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines

                            Product Name : Xeomin

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Merz Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Fol...

                            Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glabellar Frown Lines.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 16, 2019

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Merz Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Merz Aesthetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Recipient : DeNova Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Injectable Filler for Cheek Flattening

                            Details : Calcium Hydroxyapatite is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malar Deficiency.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 21, 2010

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Recipient : DeNova Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth